| Ytd | -33.30% | |
| 1y | 56.08% |
| Open | 33.64 | Prev Close | 34.19 | Low | 33.18 | High | 34.22 | Mkt Cap | 2.43B |
| Vol | 95.80K | Avg Vol | 2.08M | EPS | -5.87 | P/E | N/A | Forward P/E | -7.75 |
| Beta | 0.92 | Short Ratio | 8.21 | Inst. Own | 117.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 36.22 | 200-d Avg | 39.30 | 1yr Est | 77.14 |
The text discusses recent gains in the stock market, particularly for companies like Napco Security
Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ:VERA) with a Neutral and maintai
U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected ea
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy an
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers t
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analys
TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the p
Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises th
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and raises the
US stock futures lower with Dow down 500 points. Kura Sushi shares drop after reporting worse-than-e
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy an
B of A Securities analyst Dina Ramadane maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and
Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease dr
Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors
Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commerciali
Evercore ISI Group analyst Gavin Clark-Gartner maintains Vera Therapeutics (NASDAQ:VERA) with a O
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the anal
Wolfe Research analyst Andy Chen upgrades Vera Therapeutics (NASDAQ:VERA) from Peer Perform to Ou
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy an
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.39) per share which missed the anal
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets i
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the compan
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Gainers Asset Entities Inc. (NASDAQ: ASST) shares jumped 142% to $2.79 after the company announce
On Thursday, 63 companies set new 52-week lows.
On Wednesday, 35 companies reached new 52-week lows.
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s
During Monday's trading, 1214 companies set new 52-week lows.
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday af
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08
Gainers Newegg Commerce Inc. (NASDAQ: NEGG) shares jumped 30% to $12.03.